Keywords: orphan, status, santhera, omigapil, swiss, specialty, drug

Orphan status for Santhera's Omigapil

Article | 01 September 2008

Print This

Swiss specialty drug firm Santhera Pharmaceuticals that the US Food and Drug Administration has granted orphan drug designation to SNT-317/ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in